Nov 07, 2008 (M2 EQUITYBITES via COMTEX) -- QDHC | Quote | Chart | News | PowerRating -- QuadraMed Corporation (NASDAQ: QDHC), a company that provides IT solutions for healthcare enterprises ...
QuadraMed Corporation (NASDAQ: QDHC) announced today that it will report net income of $2.5 million before preferred stock dividends for the three months ended September 30, 2008, compared to $1.5 ...
RESTON, Va.--(BUSINESS WIRE)--QuadraMed ® Corporation (NASDAQ:QDHC) announced today that it expects to release its third quarter 2008 financial results on Thursday, November 6, 2008. Management ...
RESTON, Va.--(BUSINESS WIRE)--QuadraMed (NASDAQ:QDHC) today announced that Winchester District Memorial Hospital (WDMH), a progressive, rural-based community teaching hospital in Winchester ...
Oct 17, 2008 (M2 EQUITYBITES via COMTEX) -- QDHC | Quote | Chart | News | PowerRating -- QuadraMed Corporation (NASDAQ: QDHC), a company that provides information technology solutions for ...
RESTON, Va.--(BUSINESS WIRE)--QuadraMed Corporation (NASDAQ:QDHC) announced today that it has entered into an agreement to purchase 620,614 of its common shares from a single shareholder, at $5.50 ...
RESTON, Va.--(BUSINESS WIRE)--QuadraMed (NASDAQ:QDHC) announced today that it will showcase its Health Information Management (HIM) and Best in KLAS Smart Identity® Management solutions at the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InterSystems Corporation today announced that QuadraMed Corporation is adding InterSystems DeepSee? embedded real-time business intelligence (BI) software to a ...
RESTON, Va.--(BUSINESS WIRE)--QuadraMed Corporation (NASDAQ:QDHC) today announced that Ohio-based Ashtabula County Medical Center (ACMC) has implemented QuadraMed?s Pharmacy Integrated Medication ...
?We applaud this year?s winners for striving to maximize clinical and operational efficiencies across their enterprises by deploying state-of-the art technologies,? said Keith Hagen, QuadraMed?s ...
BOSTON (MarketWatch) -- Drug and biotechnology benchmarks moved lower in midday trading on Monday, as shares of Noven Pharmaceuticals plunged after the company reported a late-stage clinical trial showed psychiatric drug candidate Lithium QD was largely ineffective.
BOSTON (MarketWatch) -- Shares of Noven Pharmaceuticals plunged 16% to $14 after the company said that a key drug study for its psychiatric drug candidate Lithium QD had yielded disappointing results.
(Updates with additional information, executive comments, and analyst comments, and share price throughout.) NEW YORK (MarketWatch) -- Noven Pharmaceuticals Inc. said Monday that its bipolar treatment failed in a Phase III clinical study sending its shares to their lowest point in nearly two years. The Miami company said the primary objectives of the four-week study were to determine the efficacy and safety of Lithium QD compared with a placebo in the treatment of acute symptoms of mania in subjects with Bipolar I disorder. "Both the Noven and JDS teams are very surprised and disappointed that the study did not...
Noven Pharmaceuticals, Inc. said Monday that a Phase 3 clinical study of its developmental lithium carbonate product did not meet its primary endpoint with statistical significance. The company said the primary objectives of the four-week study were to determine the efficacy and safety of Lithium QD compared to placebo in the treatment of acute symptoms of mania in subjects with Bipolar I disorder. Noven, a drug development company, said it plans to complete analysis of the data and consult with the FDA regarding appropriate next steps to advance development.
LONDON (MarketWatch) -- U.K. software firm Misys said it's agreed to sell its diagnostics information business to Vista Equity Partners for $381.5 million, to sell its CPR Business hospital data sharing systems provider for $33 million in cash to QuadraMed Corp . The sale of the diagnostics information business, which is based in Tucson, Ariz. and had an annual operating profit of 23 million pounds on revenue of 79 million pounds, will need shareholder approval. Misys said it will use the cash from the deals to pay down debt and for other users, including potential acquisitions or share buy...
SAN FRANCISCO (MarketWatch) -- QAD Inc. after Thursday's closing bell cut its first-quarter and full-year 2006 forecasts, citing lower-than-expected license and services revenues and a charge of 2 cents a share related to facility exit costs. The enterprise applications provider took its first-quarter per-share forecast to a range of 6 cents to 7 cents on sales of $55 million to $56 million from a previous forecast of 12 cents to 16 cents a share in earnings on sales of between $57 million and $60 million. For the year, QAD now sees earnings of 40 cents to 50 cents a...
SAN FRANCISCO (MarketWatch) -- Joe Feshbach, who with brothers Matthew and Kurt ran one of the most infamous short-selling hedge funds of the 1980s, is back. This time, instead of betting against companies, a new hedge fund he's starting -- Joe Feshbach Partners LP -- will buy securities of troubled firms.
NEW YORK (CBS.MW) -- QuadraMed Corp. said it plans to consolidate the chief executive officer and chief operating officer positions at the end of the year. Current Chairman and CEO Lawrence English will assume both roles, and Michael Wilstead, the present COO as well as president, will step down. The Reston, Va., healthcare information technology company also increased the size of its board to nine from eight, adding James Peebles. Shares of QuadraMed closed Friday at $2.65, up a nickel.
Stocks 
